Loading...
Docoh

Oncternal Therapeutics (ONCT)

News

From Benzinga Pro
99 Biggest Movers From Yesterday
12 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
10 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Maxim Group Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $3.5
10 May 22
News, Price Target, Initiation, Analyst Ratings
Maxim Group analyst Naureen Quibria initiates coverage on Oncternal Therapeutics (NASDAQ:ONCT) with a Buy rating and announces Price Target of $3.5.
Oncternal Therapeutics Q1 EPS $(0.20), Inline
5 May 22
Earnings, News
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 66.67 percent decrease over losses of $(0.12) per share from the same period last
Earnings Scheduled For May 5, 2022
5 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Oncternal Therapeutics's Earnings Outlook
4 May 22
Earnings
Oncternal Therapeutics (NASDAQ:ONCT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Oncternal Therapeutics will report an earnings per share (EPS) of $-0.20.
66 Biggest Movers From Yesterday
3 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday.
12 Health Care Stocks Moving In Monday's Intraday Session
2 May 22
Intraday Update, Markets, Movers
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
26 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
19 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 242 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
Oncternal Discontinues Enrollment In ONCT-216 Study For Soft Tissue Cancer
13 Apr 22
Biotech, News, Penny Stocks, Health Care, General
Oncternal Therapeutics Deprioritizes Development Of ONCT-216 To Focus Resources On Phase 3 Trial For Zilovertamab In Treatment Of Mantle Cell Lymphoma ; Discontinues Enrollment In Phase 1/2 Study Of ONCT-216
13 Apr 22
Biotech, News, FDA, General
Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcoma Resources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be
Stocks That Hit 52-Week Lows On Friday
8 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's morning session, 234 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
4 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 78 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
14 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 671 companies achieved new lows for the year.
Oncternal Therapeutics Q4 EPS $(0.16) Down From $(0.09) YoY, Sales $600.00K Down From $1.59M YoY
10 Mar 22
Earnings, News
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(0.16) per share. This is a 77.78 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $600.00
Earnings Scheduled For March 10, 2022
10 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.

Press releases

From Benzinga Pro
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
5 May 22
Earnings, Press Releases
Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial of zilovertamab in
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2 May 22
Health Care, Press Releases
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
28 Apr 22
News, Press Releases
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
13 Apr 22
Press Releases
Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcomaResources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be initiated in Q3
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 22
Press Releases
SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
10 Mar 22
Earnings, Press Releases
Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on track to be initiated in
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
7 Mar 22
News, Press Releases
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 22
News, Financing, Press Releases
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has